Gilead Sciences Acquires German Biotech Tubulis for Over $3 Billion

-based pharmaceutical company, has agreed to acquire Tubulis, a biotechnology firm based in Munich, Germany, for more than $3 billion. The acquisition was reported by STAT News. This transaction involves an upfront payment and potential milestone payments based on development progress.

Tubulis focuses on developing targeted cancer therapies, particularly antibody-drug conjugates that deliver drugs directly to tumor cells. The company has been advancing several programs in early-stage clinical trials for solid tumors. Gilead, known for its work in HIV and hepatitis treatments, seeks to strengthen its position in oncology through this deal.

Companies Gilead Sciences has been expanding its oncology portfolio in recent years amid growing demand for cancer treatments.

The company reported annual revenues exceeding $27 billion in 2023, with oncology contributing a significant portion. Tubulis, founded in 2018, has raised over $100 million in funding prior to this acquisition and employs around 100 people. The acquisition includes Tubulis's lead candidates, such as those targeting HER2-positive cancers and other solid tumors.

These programs are in phase 1 trials, with data expected in the coming years. Regulatory approvals for the deal are pending, and the transaction is anticipated to close in the first half of 2025, subject to customary conditions.

This deal occurs amid a wave of mergers and acquisitions in the biotech sector, driven by large pharmaceutical companies seeking innovative pipelines.

Oncology remains a high-priority area, with global cancer drug sales projected to reach $250 billion by 2028. Stakeholders, including investors and patients, will monitor how the integration affects ongoing trials and future drug approvals. Affected parties include Tubulis employees, who may transition to Gilead's operations, and the broader biotech community in Germany.

Next steps involve integrating Tubulis's technology into Gilead's research framework and advancing clinical development. No immediate changes to existing programs have been announced.